Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: Combined consequences for cell therapy in older recipients

Zhuo, Yufeng; Li, Shuhong; Chen, Minsheng; Wu, Jun; Kinkaid, Heather Y. McDonald; Fazel, Shafie; Weisel, Richard D.; Li, Ren‐Ke

doi:10.1016/j.jtcvs.2009.08.052

Cited by 92 publications

(78 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether the routine use of older donors with depressed ventricular function would yield the same results cannot be ascertained from the current study. Aging has been found to reduce the angiogenic response to ischemic injury in animal models 24 and result in greater ischemia reperfusion injury and apoptosis. 25,26 A loss of cardioprotection and a decreased response to ischemic precondition have also been noted with aging, 27,28 although this has not been consistent across all studies.…”

Section: Discussionmentioning

confidence: 99%

Pediatric Heart Transplantation From Donors With Depressed Ventricular Function

Rossano

Lin

Paridon

et al. 2013

Circ: Heart Failure

View full text Add to dashboard Cite

Background— Wait-list mortality for children awaiting heart transplantation remains high. Potential donor hearts with depressed ventricular function are often declined. We aimed to test the hypothesis that pediatric heart transplant recipients of grafts with depressed ventricular function would have comparable survival with those with normal function. Methods and Results— A retrospective study was performed for pediatric heart transplants from the United Network of Organ Sharing Database from October 26, 1999, to June 30, 2011. Patients were grouped based on accepted donor left ventricular ejection fraction (LVEF): normal function (LVEF ≥55%), mildly depressed function (LVEF 45%–54%), or moderately-to-severely depressed function (LVEF <45%). During the study period, there were 3672 pediatric heart transplants; 3306 (90%) had a LVEF reported. Ventricular function was mildly depressed in 245 (7%) and moderately-to-severely depressed in 172 (5%). Patients receiving grafts with moderately-to-severely depressed function were more likely to be younger and weigh less ( P <0.001 for both) than those receiving grafts with normal function. Median graft survival from accepted donors with normal ventricular function (10.6 years) was similar to survival from accepted donors with mildly depressed ventricular function (9.7 years; P =0.24) and from accepted donors with moderately-to-severely depressed ventricular function (9.1 years; P =0.13). On propensity-matched analysis, donor ventricular function was not associated with graft survival. Conclusions— The use of donors with depressed ventricular function is uncommon in pediatric heart transplantation (<15% of all transplants), yet graft survival does not differ significantly from accepted donors with normal ventricular function. Hearts from donors with depressed ventricular function may be considered in selected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Pediatric Heart Transplantation From Donors With Depressed Ventricular Function

Rossano

Lin

Paridon

et al. 2013

Circ: Heart Failure

View full text Add to dashboard Cite

show abstract

“…In addition, animals used in these studies are usually healthy and young, as opposed to patients with CLI. This is even more relevant because it has been shown that age impairs the angiogenic response (Zhuo et al, 2010).…”

Section: The Hindlimb Ischemia Modelmentioning

confidence: 99%

Gene Therapy with Non-Viral Vectors For Critical Limb Ischemia: From Bench to Bedside

Paula¹

2011

Gene Therapy Applications

View full text Add to dashboard Cite

“…Furthermore, most patients who could benefit from such therapy are elderly patients with multiple medical comorbidities. Unfortunately a number of recent studies have documented that MSCs obtained from elderly donors, and those with diabetes, renal failure or severe ischemic heart disease, demonstrate significantly reduced capacity for proliferation, differentiation and neovascularization, with increased levels of apoptosis in vitro and in vivo [4]. Such impaired autologous cells from sick elderly patients could therefore limit their therapeutic potential.…”

mentioning

confidence: 99%

“…For instance, in their study, MSCs were harvested from the sternum of patients undergoing cardiac surgery. These cells, taken from elderly donors, were previously shown to have a significantly lower capacity for differentiation, angiogenesis, survival and even proliferation [4]. It is of interest to note that in the in vitro studies, human MSCs used were instead harvested from young healthy donors.…”

mentioning

confidence: 99%